ArticleArthroplasty today2026
A Carbon Monoxide Breathalyzer is Effective at Identifying Smokers Before Total Joint Arthroplasty.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Smoking is a major risk factor for delayed wound healing and prosthetic joint infections, yet it is poorly identified and modified before surgery. Patients often omit or downplay their consumption, and objective methods of screening for smoking are lacking. Carbon monoxide (CO) breath testing is a validated, noninvasive tool to detect recent smoking but has yet to be used to screen patients planned for total joint arthroplasty (TJA). This study compares self-reported smoking status to a CO breathalyzer test in patients listed for TJA. Methods: We conducted a cross-sectional study of patients with end-stage arthritis listed for TJA surgery at a single academic center. All participants completed a standardized smoking questionnaire and then underwent CO breath testing using a validated handheld breathalyzer. CO levels were categorized as low (0-6 ppm), borderline (7-9 ppm), or high (≥10 ppm). The primary outcome was the concordance between self-reported smoking status and CO levels. Results: A total of 153 patients were enrolled, of whom 29 self-identified as Conclusions: CO breath testing is a low-cost, noninvasive tool that successfully differentiated between self-reported active smokers and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.